人 pTau202/205 抗体对
01AB00092
Phosphorylated tau at position 205 (p-tau205) has emerged as a significant biomarker for tau pathology in Alzheimer's disease (AD). Recent studies indicate that p-tau205 levels increase progressively across the AD continuum, correlating strongly with neurofibrillary tangles rather than amyloid plaques, which are typically associated with earlier stages of the disease. This biomarker demonstrates robust associations with tau-PET imaging, particularly in advanced Braak stages of tau pathology, suggesting its potential utility in staging and monitoring disease progression. CSF p-tau205 is also linked to cognitive decline, highlighting its relevance in clinical settings for diagnosing and tracking AD. Its specificity for tau pathology positions it as a promising alternative to traditional imaging methods in both research and clinical trials aimed at developing AD therapies.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- MAPT
- 基因别名
- MAPTL; MTBT1; TAU
- 蛋白别名
- Microtubule-associated protein tau; pTau202/205
- UniProt
- P10636-8
- 物种
- Human
产品详情
- 靶点名称
- pTau202/205
- 蛋白名称
- Microtubule-associated protein tau
- 靶点基因名
- MAPT
- 基因别名
- MAPTL; MTBT1; TAU
- UniProt
- P10636-8
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Phosphorylated tau at position 205 (p-tau205) has emerged as a significant biomarker for tau pathology in Alzheimer's disease (AD). Recent studies indicate that p-tau205 levels increase progressively across the AD continuum, correlating strongly with neurofibrillary tangles rather than amyloid plaques, which are typically associated with earlier stages of the disease. This biomarker demonstrates robust associations with tau-PET imaging, particularly in advanced Braak stages of tau pathology, suggesting its potential utility in staging and monitoring disease progression. CSF p-tau205 is also linked to cognitive decline, highlighting its relevance in clinical settings for diagnosing and tracking AD. Its specificity for tau pathology positions it as a promising alternative to traditional imaging methods in both research and clinical trials aimed at developing AD therapies.